ReviewClinical and translational allergy2025
Advances in the Gut-Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential.
Review in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Metabolic Reprogramming and ILC2 Plasticity in Obesity-related Asthma.Clinical reviews in allergy & immunology · 2026Review
- Live tissue microbiota and bacterial translocation: mechanisms and translational perspectives in cardiometabolic diseases.Reviews in endocrine & metabolic disorders · 2026Review
- Multi-Kingdom Fecal Microbiota Alterations in Horses with Severe Equine Asthma.Microorganisms · 2026Article
- The role of intestinal microbiota in the pathogenesis of childhood asthma.Frontiers in immunology · 2026Review
- Advances in the Gut-Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential.Clinical and translational allergy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBronchial asthma (hereafter referred to as asthma) is a heterogeneous disease characterized by chronic airway inflammation, airway hyperresponsiveness (AHR), and reversible airflow limitation. Recent advancements in the "gut-lung" axis concept have elucidated the intricate immunometabolic crosstalk between the gastrointestinal tract and pulmonary system, offering novel insights into the pathogenesis and therapeutic strategies for asthma.
objectiveExploring the research progress of the "gut-lung" axis in bronchial asthma, providing new insights into the pathogenesis and treatment of asthma.
methodsThis article reviewed a large number of relevant studies, elucidating the role of the "gut-lung" axis in bronchial asthma, and further discussing the potential of the microbiota in the treatment of bronchial asthma.
conclusionGut microbiota and their metabolites exert profound effects on pulmonary immune homeostasis through immune modulation, metabolic signaling, and neuroendocrine pathways, which are critically implicated in asthma pathogenesis. Conversely, systemic immune dysregulation in asthma may reciprocally induce intestinal barrier dysfunction. Asthma is a variable disease here. It may be that some of this variability relates to different diets or environmental/gut exposures although this needs to be confirmed in human studies. This review comprehensively delineates the mechanistic role of the gut-lung axis in asthma, encompassing microbiota-immune system interactions, regulatory effects of microbial-derived metabolites such as short-chain fatty acids (SCFAs) and bile acids, and microbiota-targeted therapeutic approaches including probiotics, dietary interventions, and metabolite-based therapies. Furthermore, we also discuss the limitations and future development directions of current research to provide new ideas for precision treatment of asthma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.